Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016
Published Jun 08, 2016
46 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016, provides an overview of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
- The report reviews pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics and enlists all their major and minor projects
- The report assesses Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain

  
Source:
Document ID
GMDHC8208IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview61
Therapeutics Development72
  Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview71
  Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Comparative Analysis81
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics under Development by Companies91
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics under Investigation by Universities/Institutes101
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Pipeline Products Glance112
  Clinical Stage Products111
  Early Stage Products121
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Products under Development by Companies131
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Products under Investigation by Universities/Institutes141
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Companies Involved in Therapeutics Development155
  Destiny Pharma Limited151
  Galapagos NV161
  MGB Biopharma Limited171
  Syntiron LLC181
  Techulon, Inc.191
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics Assessment209
  Assessment by Monotherapy Products201
  Assessment by Target212
  Assessment by Mechanism of Action232
  Assessment by Route of Administration252
  Assessment by Molecule Type272
Drug Profiles2911
  acALY-18 - Drug Profile291
    Product Description291
    Mechanism of Action291
    R&D Progress291
  Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile301
    Product Description301
    Mechanism of Action301
    R&D Progress301
  exeporfinium chloride - Drug Profile311
    Product Description311
    Mechanism of Action311
    R&D Progress312
  GLPG-1492 - Drug Profile331
    Product Description331
    Mechanism of Action331
    R&D Progress331
  MGBBP-3 - Drug Profile341
    Product Description341
    Mechanism of Action341
    R&D Progress342
  MH-003 - Drug Profile361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile371
    Product Description371
    Mechanism of Action371
    R&D Progress371
  Siderocillin - Drug Profile381
    Product Description381
    Mechanism of Action381
    R&D Progress381
  Staphylococcus aureus vaccine - Drug Profile391
    Product Description391
    Mechanism of Action391
    R&D Progress391
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Recent Pipeline Updates402
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects421
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Discontinued Products431
Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Product Development Milestones441
  Featured News &Press Releases441
    Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections441
Appendix452
  Methodology451
  Coverage451
  Secondary Research451
  Primary Research451
  Expert Panel Validation451
  Contact Us451
  Disclaimer461

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hospital-Acquired-Methicillin-Resistant-Staphylococcus-aureus-HA-MRSA-Infections-Pipeline-Review-H1-2016-2088-15929>
  
APA:
Global Markets Direct - Market Research. (2016). Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hospital-Acquired-Methicillin-Resistant-Staphylococcus-aureus-HA-MRSA-Infections-Pipeline-Review-H1-2016-2088-15929>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.